Hvilken er prisen på Hybio Pharmaceutical Co., Ltd. (300199)

Prisen på Hybio Pharmaceutical Co., Ltd. (300199) er $3.32

Hva er markedsverdien på Hybio Pharmaceutical Co., Ltd. (300199)

Markedsverdien på Hybio Pharmaceutical Co., Ltd. (300199) er $2.93B

Hybio Pharmaceutical Co., Ltd. (300199) Aksjesplitter

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

År	Splitt	Multiplikator	Kumulativ multiplikator
Ikke nok data for de angitte datoene.

År

Splitt

Multiplikator

Kumulativ multiplikator

Ikke nok data for de angitte datoene.

Selskap	Antall aksjesplitt	Kumulativ multiplikator	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Selskap

Antall aksjesplitt

Kumulativ multiplikator

Land